drugset / Trial / NCT05607420
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Timeline
- Start
- 2022-11-01
- Primary completion
- 2027-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UCART20x22 | Cell therapy | — | Intravenous |
| Background | Alemtuzumab | Monoclonal antibody | — | — |